Market closed

Cue Biopharma/$CUE

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Ticker

$CUE

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

Website

www.cuebiopharma.com

Cue Biopharma Metrics

BasicAdvanced

$85M

-

-$0.90

1.63 -

Price and volume

Market cap

$85M

Beta

1.63

52-week high

$3.03

52-week low

$0.45

Average daily volume

377K

Financial strength

Current ratio

2.219

Quick ratio

2.119

Long term debt to equity

10.463

Total debt to equity

37.499

Interest coverage (TTM)

-39.69%

Management effectiveness

Return on assets (TTM)

-50.18%

Return on equity (TTM)

-131.15%

Valuation

Price to revenue (TTM)

6.961

Price to book

3.18

Price to tangible book (TTM)

3.18

Price to free cash flow (TTM)

-1.731

Growth

Revenue change (TTM)

149.53%

Earnings per share change (TTM)

-24.04%

3-year revenue growth (CAGR)

10.00%

3-year earnings per share growth (CAGR)

-15.97%

What the Analysts think about Cue Biopharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cue Biopharma stock.

Cue Biopharma Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Cue Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Cue Biopharma News

AllArticlesVideos

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·2 months ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewsWire·2 months ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CUE

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cue Biopharma stock?

Cue Biopharma (CUE) has a market cap of $85M as of January 15, 2025.

What is the P/E ratio for Cue Biopharma stock?

The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of January 15, 2025.

Does Cue Biopharma stock pay dividends?

No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Cue Biopharma dividend payment date?

Cue Biopharma (CUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Cue Biopharma?

Cue Biopharma (CUE) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.